7.10
+22.20%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Exagen
From its filings with the US Securities and Exchange Commission
Exagen is based in Vista, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker XGN. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $66.6m and a net loss of $20.0m. At that date it held total assets of $58.0m and shareholders' equity of $17.4m.
We are a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under our AVISE® brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). We believe our strong focus and extensive background in the field of rheumatology, combined with our commitment to exceptional customer service and support, position us well to respond to the needs of rheumatologists, primary care physicians, other specialists, and the patients they serve.
Our tests are used in a variety of clinical settings to provide clarity in autoimmune disease decision-making with the goal of improving patients' clinical outcomes. We commercially launched our flagship testing product, AVISE® CTD, in 2012. AVISE® CTD enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. Traditional screening methods often lack accuracy, resulting in repeat testing and delayed diagnosis. With significant increases in autoimmune incidence in recent years, AVISE® CTD provides unique biomarkers that empower clinicians to confidently and quickly diagnose various CTDs.
Quoted from its 10-K, filed 10 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 19 Sept 2019
- Employees
- 216
- Website
- exagen.com ↗
- Head office
- 1261 LIBERTY WAY, VISTA, CA, 92081
- Incorporated in
- DE
- Classification
- Services-Medical Laboratories
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Tina NovaExecutive Chairman of the Board, since 2019$126,865
- Mr. John AballiPresident, Chief Executive Officer, Director, since 2022$1.2m
- Mr. Jeffrey BlackChief Financial Officer, Corporate Secretary$1.0m
- Ms. Ana HookerIndependent Director$83,368
- Dr. Scott KahnIndependent Director$49,711
- Mr. Paul KimIndependent Director$82,910
- Mr. Charles MckhannIndependent Director
- Dr. Bruce RobertsonIndependent Director$33,750
- Mr. Frank StokesIndependent Director$79,910
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 46
- Environment
- 22
- Social
- 56
- Governance
- 61
- Women in the workforce
- 65%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Exagen Inc has several strengths that contribute to its success in the market. One major strength is its advanced technology and innovative approach to diagnostic testing. This allows the company to provide accurate and reliable results, which in turn enhances its reputation and customer trust. Additionally, Exagen Inc has a strong team of skilled professionals who are experts in their respective fields, enabling the company to deliver high-quality services.
Weaknesses
- Despite its strengths, Exagen Inc also faces certain weaknesses that need to be addressed. One weakness is its limited market presence, particularly in certain geographical regions. Expanding into these untapped markets could lead to increased growth opportunities. Moreover, Exagen Inc may face challenges in differentiating its offerings from competitors, as the diagnostic testing industry is highly competitive and constantly evolving.
Opportunities
- Exagen Inc has various opportunities to capitalize on in order to further its success. The increasing demand for personalized medicine and precision diagnostics presents a significant opportunity for the company. By aligning its services with these emerging trends, Exagen Inc can attract new customers and gain a competitive edge. Furthermore, strategic partnerships with healthcare providers and research institutions can help Exagen Inc expand its reach and develop new diagnostic products.
Threats
- Exagen Inc operates in an industry that is subject to certain threats, which must be carefully managed. One threat is the potential for regulatory changes and compliance requirements, which can impact the company's operations and increase costs. Additionally, the presence of new entrants and established competitors in the market poses a threat to Exagen Inc's market share. Staying vigilant and continuously innovating will be crucial to maintaining a competitive position in the industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.